1
|
Park CG, Lee SY, Kandala G, Lee SY and
Choi Y: A novel gene product that couples TCR signaling to
Fas(CD95) expression in activation-induced cell death. Immunity.
4:583–591. 1996. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kuske MD and Johnson JP: Assignment of the
human PHLDA1 gene to chromosome 12q15 by radiation hybrid mapping.
Cytogenet Cell Genet. 89:12000. View Article : Google Scholar : PubMed/NCBI
|
3
|
Neef R, Kuske MA, Pröls E and Johnson JP:
Identification of the human PHLDA1/TDAG51 gene: Down-regulation in
metastatic melanoma contributes to apoptosis resistance and growth
deregulation. Cancer Res. 62:5920–5929. 2002.PubMed/NCBI
|
4
|
Hayashida N, Inouye S, Fujimoto M, Tanaka
Y, Izu H, Takaki E, Ichikawa H, Rho J and Nakai A: A novel
HSF1-mediated death pathway that is suppressed by heat shock
proteins. EMBO J. 25:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Nagai MA, Fregnani JH, Netto MM, Brentani
MM and Soares FA: Down-regulation of PHLDA1 gene expression is
associated with breast cancer progression. Breast Cancer Res Treat.
106:49–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Coutinho-Camillo CM, Lourenço SV, Nonogaki
S, Vartanian JG, Nagai MA, Kowalski LP and Soares FA: Expression of
PAR-4 and PHLDA1 is prognostic for overall and disease-free
survival in oral squamous cell carcinomas. Virchows Arch.
463:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Murata T, Sato T, Kamoda T, Moriyama H,
Kumazawa Y and Hanada N: Differential susceptibility to hydrogen
sulfide-induced apoptosis between PHLDA1-overexpressing oral cancer
cell lines and oral keratinocytes: Role of PHLDA1 as an apoptosis
suppressor. Exp Cell Res. 320:247–257. 2014. View Article : Google Scholar
|
8
|
Park ES, Kim J, Ha TU, Choi JS, Soo Hong K
and Rho J: TDAG51 deficiency promotes oxidative stress-induced
apoptosis through the generation of reactive oxygen species in
mouse embryonic fibroblasts. Exp Mol Med. 45:e352013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hinz T, Flindt S, Marx A, Janssen O and
Kabelitz D: Inhibition of protein synthesis by the T cell
receptor-inducible human TDAG51 gene product. Cell Signal.
13:345–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Johnson EO, Chang KH, de Pablo Y, Ghosh S,
Mehta R, Badve S and Shah K: PHLDA1 is a crucial negative regulator
and effector of Aurora A kinase in breast cancer. J Cell Sci.
124:2711–2722. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Otto T, Horn S, Brockmann M, Eilers U,
Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R,
Christiansen H, et al: Stabilization of N-Myc is a critical
function of Aurora A in human neuroblastoma. Cancer Cell. 15:67–78.
2009. View Article : Google Scholar
|
12
|
Shang X, Burlingame SM, Okcu MF, Ge N,
Russell HV, Egler RA, David RD, Vasudevan SA, Yang J and Nuchtern
JG: Aurora A is a negative prognostic factor and a new therapeutic
target in human neuroblastoma. Mol Cancer Ther. 8:2461–2469. 2009.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Brockmann M, Poon E, Berry T, Carstensen
A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et
al: Small molecule inhibitors of aurora-a induce proteasomal
degradation of N-myc in childhood neuroblastoma. Cancer Cell.
24:75–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mossé YP, Lipsitz E, Fox E, Teachey DT,
Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH and Blaney SM:
Pediatric phase I trial and pharmacokinetic study of MLN8237, an
investigational oral selective small-molecule inhibitor of Aurora
kinase A: A Children's Oncology Group Phase I Consortium study.
Clin Cancer Res. 18:6058–6064. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Huang M and Weiss WA: Neuroblastoma and
MYCN. Cold Spring Harb Perspect Med. 3:a0144152013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Dhillon S: Dinutuximab: First global
approval. Drugs. 75:923–927. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Horwacik I, Durbas M, Boratyn E, Węgrzyn P
and Rokita H: Targeting GD2 ganglioside and Aurora A kinase as a
dual strategy leading to cell death in cultures of human
neuroblastoma cells. Cancer Lett. 341:248–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kowalczyk A, Gil M, Horwacik I, Odrowaz Z,
Kozbor D and Rokita H: The GD2-specific 14G2a monoclonal antibody
induces apoptosis and enhances cytotoxicity of chemotherapeutic
drugs in IMR-32 human neuroblastoma cells. Cancer Lett.
281:171–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng
J, Sun J and Yang G: Aurora-A: A potential DNA repair modulator.
Tumour Biol. 35:2831–2836. 2014. View Article : Google Scholar
|
20
|
Dorn GW II and Kitsis RN: The
mitochondrial dynamism-mitophagy-cell death interactome: Multiple
roles performed by members of a mitochondrial molecular ensemble.
Circ Res. 116:167–182. 2015. View Article : Google Scholar :
|
21
|
Riccardi C and Nicoletti I: Analysis of
apoptosis by propidium iodide staining and flow cytometry. Nat
Protoc. 1:1458–1461. 2006. View Article : Google Scholar
|
22
|
Stock C, Bozsaky E, Watzinger F,
Poetschger U, Orel L, Lion T, Kowalska A and Ambros PF: Genes
proximal and distal to MYCN are highly expressed in human
neuroblastoma as visualized by comparative expressed sequence
hybridization. Am J Pathol. 172:203–214. 2008.Erratum in: Am J
Pathol 172: 1153, 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wang L, Wang G, Yang D, Guo X, Xu Y, Feng
B and Kang J: Euphol arrests breast cancer cells at the G1 phase
through the modulation of cyclin D1, p21 and p27 expression. Mol
Med Rep. 8:1279–1285. 2013.PubMed/NCBI
|
24
|
Durbas M, Horwacik I, Boratyn E, Kamycka E
and Rokita H: GD2 ganglioside specific antibody treatment
downregulates PI3K/Akt/mTOR signaling network in human
neuroblastoma cell lines. Int J Oncol. 47:1143–1159.
2015.PubMed/NCBI
|
25
|
Horwacik I, Durbas M, Boratyn E, Sawicka
A, Węgrzyn P, Krzanik S, Górka A, Drożniak J, Augustyniak E,
Kowalczyk A, et al: Analysis of genes involved in response to
doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal
antibody in IMR-32 human neuroblastoma cells. Acta Biochim Pol.
62:423–433. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Matsumura S, Terao M, Murota H and
Katayama I: Th2 cytokines enhance TrkA expression, upregulate
proliferation, and downregulate differentiation of keratinocytes. J
Dermatol Sci. 78:215–223. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Bao W, Qiu H, Yang T, Luo X, Zhang H and
Wan X: Upregulation of TrkB promotes epithelial-mesenchymal
transition and anoikis resistance in endometrial carcinoma. PLoS
One. 8:e706162013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Zuccato C, Marullo M, Vitali B, Tarditi A,
Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, et
al: Brain-derived neurotrophic factor in patients with Huntington's
disease. PLoS One. 6:e229662011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Gu YM, Ma YH, Zhao WG and Chen J:
Dickkopf3 overexpression inhibits pancreatic cancer cell growth in
vitro. World J Gastroenterol. 17:3810–3817. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Skalniak A, Boratyn E, Tyrkalska SD,
Horwacik I, Durbas M, Lastowska M, Jura J and Rokita H: Expression
of the monocyte chemotactic protein-1-induced protein 1 decreases
human neuroblastoma cell survival. Oncol Rep. 31:2385–2392.
2014.PubMed/NCBI
|
31
|
Dupasquier S, Delmarcelle AS, Marbaix E,
Cosyns JP, Courtoy PJ and Pierreux CE: Validation of housekeeping
gene and impact on normalized gene expression in clear cell renal
cell carcinoma: Critical reassessment of YBX3/ZONAB/CSDA
expression. BMC Mol Biol. 15:92014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Smith PK, Krohn RI, Hermanson GT, Mallia
AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and
Klenk DC: Measurement of protein using bicinchoninic acid. Anal
Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI
|
33
|
Edsjö A, Nilsson H, Vandesompele J,
Karlsson J, Pattyn F, Culp LA, Speleman F and Påhlman S:
Neuroblastoma cells with overexpressed MYCN retain their capacity
to undergo neuronal differentiation. Lab Invest. 84:406–417. 2004.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Maris JM: Unholy matrimony: Aurora A and
N-Myc as malignant partners in neuroblastoma. Cancer Cell. 15:5–6.
2009. View Article : Google Scholar
|
35
|
Yang H, He L, Kruk P, Nicosia SV and Cheng
JQ: Aurora-A induces cell survival and chemoresistance by
activation of Akt through a p53-dependent manner in ovarian cancer
cells. Int J Cancer. 119:2304–2312. 2006. View Article : Google Scholar : PubMed/NCBI
|
36
|
Brodeur GM, Minturn JE, Ho R, Simpson AM,
Iyer R, Varela CR, Light JE, Kolla V and Evans AE: Trk receptor
expression and inhibition in neuroblastomas. Clin Cancer Res.
15:3244–3250. 2009. View Article : Google Scholar : PubMed/NCBI
|
37
|
Tacconelli A, Farina AR, Cappabianca L,
Desantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B,
Screpanti I, et al: TrkA alternative splicing: A regulated
tumor-promoting switch in human neuroblastoma. Cancer Cell.
6:347–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
38
|
Haapasalo A, Sipola I, Larsson K, Akerman
KE, Stoilov P, Stamm S, Wong G and Castren E: Regulation of TRKB
surface expression by brain-derived neurotrophic factor and
truncated TRKB isoforms. J Biol Chem. 277:43160–43167. 2002.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Li Z, Tan F, Liewehr DJ, Steinberg SM and
Thiele CJ: In vitro and in vivo inhibition of neuroblastoma tumor
cell growth by AKT inhibitor perifosine. J Natl Cancer Inst.
102:758–770. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Li Z, Jaboin J, Dennis PA and Thiele CJ:
Genetic and pharmacologic identification of Akt as a mediator of
brain-derived neurotrophic factor/TrkB rescue of neuroblastoma
cells from chemotherapy-induced cell death. Cancer Res.
65:2070–2075. 2005. View Article : Google Scholar : PubMed/NCBI
|
41
|
Motti ML, De Marco C, Califano D, Fusco A
and Viglietto G: Akt-dependent T198 phosphorylation of
cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell
Cycle. 3:1074–1080. 2004. View Article : Google Scholar : PubMed/NCBI
|
42
|
Viglietto G, Motti ML and Fusco A:
Understanding p27(kip1) deregulation in cancer: Down-regulation or
mislocalization. Cell Cycle. 1:394–400. 2002. View Article : Google Scholar
|
43
|
Perry SW, Norman JP, Barbieri J, Brown EB
and Gelbard HA: Mitochondrial membrane potential probes and the
proton gradient: A practical usage guide. Biotechniques. 50:98–115.
2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Li MX and Dewson G: Mitochondria and
apoptosis: Emerging concepts. F1000Prime Rep. 7:422015.PubMed/NCBI
|
46
|
Zhao J, Zhang J, Yu M, Xie Y, Huang Y,
Wolff DW, Abel PW and Tu Y: Mitochondrial dynamics regulates
migration and invasion of breast cancer cells. Oncogene.
32:4814–4824. 2013. View Article : Google Scholar
|
47
|
Gottlieb E, Vander Heiden MG and Thompson
CB: Bcl-x(L) prevents the initial decrease in mitochondrial
membrane potential and subsequent reactive oxygen species
production during tumor necrosis factor alpha-induced apoptosis.
Mol Cell Biol. 20:5680–5689. 2000. View Article : Google Scholar : PubMed/NCBI
|